MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Inflammation"

  • MDS Virtual Congress 2020

    A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)

    E. Rawner, J. Powell, S. Minami, K. Tang, V. Klutzaritz, E. McCaskill Newman, J. Hannestad (San Carlos, CA, USA)

    Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…
  • MDS Virtual Congress 2020

    Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease

    M. Schiess, J. Suescun, M. Doursout, C. Adams, C. Green, J. Saltarrelli, S. Savitz, T. Ellmore (Houston, TX, USA)

    Objective: Prove safety and feasibility of delivering allogeneic bone marrow-derived mesenchymal stem cells (MSC) intravenously in escalated doses to patients with idiopathic Parkinson’s disease (PD).…
  • MDS Virtual Congress 2020

    Development and validation of a profile of peripheral immune biomarkers for Parkinson’s disease: A multicenter, retrospective study

    Y. Li, J. Liu (Shanghai, China)

    Objective: This multicenter study was designed to investigate the association between multiple peripheral immune biomarkers and the risk of Parkinson’s disease (PD). Background: Several studies…
  • MDS Virtual Congress 2020

    Predicting the effects of Tumor Necrosis Factor inhibition on the risk and age at onset of Parkinson’s disease: A Mendelian randomization study

    X. Kang, A. Ploner, N. Pedersen, J. Ludvigsson, S. Bandres-Ciga, A. Noyce, K. Wirdefeldt, D. Williams (Stockholm, Sweden)

    Objective: To evaluate whether inhibition of Tumor Necrosis Factor (TNF) signaling may reduce the risk of Parkinson’s disease (PD) and/or delay onset of PD. Background:…
  • MDS Virtual Congress 2020

    Neuroinflammation and Myelin changes in MSA-P evaluated using Advanced Diffusion MRI and Myelin Sensitive Imaging Techniques

    T. Ogawa, T. Hatano, K. Kamagata, C. Andica, H. Takeshige-Amano, W. Uchida, D. Kamiyama, Y. Shimo, G. Oyama, A. Umemura, H. Iwamuro, M. Ito, M. Hori, S. Aoki, N. Hattori (Tokyo, Japan)

    Objective: To determine more specific neuropathologies of the white matter in patients with multiple system atrophy-parkinsonian variant (MSA-P) using multi-shell diffusion magnetic resonance imaging (MRI)…
  • 2019 International Congress

    CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson’s disease

    Y. Li, M. Niu, J. Liu (Shanghai, China)

    Objective: Activated microglia and increased cytokine levels could precede neurodegeneration in neuro-inflammation in A53T mice, and CXCL12 was found increased in plasma CNS-derived exosomes, which…
  • 2019 International Congress

    The role of the gut microbial dysbiosis and serum inflammatory profile for the discrimination of clinical subtypes in Parkinson’s disease

    I. Miliukhina, E. Ermolenko, E. Gracheva, A. Istomina, M. Kotyleva, E. Agapova, A. Suvorov (Saint-Petersburg, Russian Federation)

    Objective: To investigate whether clinical phenotypes can be predicted by the assessment of gut microbiome and serum inflammatory profile of PD patients. Background: Recent evidence…
  • 2019 International Congress

    Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist

    A. Pinna, G. Costa, M. Serra, M. Morelli (Monserrato, Italy)

    Objective: To evaluate whether an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A receptor antagonist preladenant prevent the onset of…
  • 2019 International Congress

    The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson’s disease

    I. Rektor, B. Vesely, N. Bohnen, E. Koritakova, E. Kurca, P. Valkovic (Brno, Czech Republic)

    Objective: To examine the contributions of systemic factors to clinically relevant cognitive decline in Parkinson’s disease (PD), we studied the impact of cardiometabolic and inflammatory…
  • 2019 International Congress

    Serum Inflammatory Profile for the Discrimination of tremor severity in essential tremor

    Z. Muruzheva, D. Traktirov, I. Ivleva, V. Maystrenko, M. Karpenko (Saint-Petersburg, Russian Federation)

    Objective: To establish the correlation between cytokines level in the serum of patients with ET and disease severity. Background: Essential tremor (ET) is the most…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 22
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • “Striatal Hand Signs” and early diagnosis of Parkinson's Disease: The “Monkey-Wrench Sign”.
  • An atypical and interesting feature of Parkinson´s disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley